Related Experiment Videos
Surrogate and Intermediate Endpoints in Randomized Trials: What's the Goal?
Edward L Korn1, Boris Freidlin2
1Biometric Research Program, National Cancer Institute, Bethesda, Maryland. korne@ctep.nci.nih.gov.
Summary
Establishing intermediate endpoints to predict survival benefit in clinical trials is difficult. However, these endpoints offer valuable applications in drug development and patient care.
Area of Science:
- Oncology
- Clinical Trials
- Drug Development
Background:
- Intermediate endpoints are crucial in clinical trials for assessing drug efficacy.
- Predicting long-term survival benefit using intermediate endpoints is complex due to extrapolation challenges.
Purpose of the Study:
- To discuss the challenges of establishing trial-level surrogacy for intermediate endpoints.
- To highlight alternative applications of intermediate endpoints in oncology drug development and patient management.
Main Methods:
- Review of existing methodologies for intermediate endpoint validation.
- Analysis of case studies in cancer research where intermediate endpoints were utilized.
Main Results:
- Trial-level surrogacy for predicting survival benefit remains a significant challenge.
- Intermediate endpoints demonstrate utility in accelerating drug development timelines.
- These endpoints aid in making informed patient management decisions.
Conclusions:
- While direct prediction of survival benefit is difficult, intermediate endpoints serve critical roles.
- Further research is needed to refine the use of intermediate endpoints in clinical trial design.
- Optimizing the application of intermediate endpoints can improve cancer drug development and patient outcomes.